Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4 Purity >98.0% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Pure
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Ingoa matū | Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate |
Nga kupu taurite | Lenvatinib poke 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acid Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acid Methyl Ester;Lenvaint-D |
Tau CAS | 205448-66-4 |
Tau CAT | RF-PI1970 |
Tūnga Taonga | I roto i te Stock, Production Tauine Up ki Taranata |
Tātai rāpoi | C12H10ClNO3 |
Taumaha rāpoi | 251.67 |
Kohuatanga | 377.4±37.0℃ |
Kiato | 1.320±0.06 g/cm3 |
Waitohu | Ruifu Chemical |
Tūemi | Whakatakotoranga |
Te ahua | Paura-White ki te Paura Toka Kowhai |
1 H NMR Spectrum | E rite ana ki te Hanganga |
Te Maama / Tikanga Tatauria | >98.0% (HPLC) |
Ngaronga i te whakamaroke | <1.00% |
Nga poke katoa | <2.00% |
Paerewa Whakamatau | Paerewa hinonga |
Whakamahinga | Takawaenga/Parakore o Lenvatinib Mesylate (CAS: 857890-39-2) |
Mōkī: Pounamu, Peeke konumohe konumohe, 25kg / Kaata Drum, kia rite ranei ki te hiahia a te kaihoko
Tikanga Rokiroki:Whakaorangia i roto i nga ipu kua hiri ki te waahi makariri me te maroke;Tiaki i te marama me te makuku
Ko te Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate (CAS: 205448-66-4) he takawaenga o Lenvatinib Mesylate (CAS: 857890-39-2).Ko Lenvatinib he rongoa mate pukupuku thyroid i whakawhanakehia e Eisai Corporation o Hapani (Waehere: E7080), no roto i te aukati o te waha maha-receptor tyrosine kinase (RTK) a ka taea te aukati i te mahi kinase o te vascular endothelial growth factor Receptors R1 (FLT1), VEG-FR2 (KDR), R3 (FLT4).Ka taea hoki e Lenvatinib te whakakore i te whakauru o etahi atu RTK i roto i te angiogenesis pathological, te tipu o te pukupuku, me te haere o te mate pukupuku engari mo o raatau mahi pūtau noa tae atu ki te fibroblast growth factor (FGF) nga kaiwhiwhi FGFR1, 2, 3, me te 4;te kaikawe tauwehe tipu i ahu mai i te platelet (PDGFR [alpha]), KIT, me te RET.[Nga Tohu]: He pai a Lenvatinib mo te maimoatanga o nga turoro o te mate pukupuku taikaro o te hokinga mai o te rohe, te momo metastasis ranei, te momo ahunga whakamua me te momo rerekee o te iodine-refractory radioactive.